Literature DB >> 20062096

Development of severe sclerotic chronic GVHD during treatment with dasatinib.

D Pulanic, E W Cowen, K Baird, M R Bishop, S Z Pavletic.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20062096      PMCID： PMC7365192          DOI： 10.1038/bmt.2009.368

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  10 in total

1.  Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect?

Authors:  M Breccia; L Cannella; C Stefanizzi; A Carotti; M Santopietro; G Alimena
Journal:  Bone Marrow Transplant       Date:  2009-02-16       Impact factor: 5.483

2.  Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease.

Authors:  Michael Stadler; Renate Ahlborn; Haytham Kamal; Helmut Diedrich; Stefanie Buchholz; Matthias Eder; Arnold Ganser
Journal:  Blood       Date:  2009-10-22       Impact factor: 22.113

3.  Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis.

Authors:  Craig E Daniels; Mark C Wilkes; Maryanne Edens; Ted J Kottom; Stephen J Murphy; Andrew H Limper; Edward B Leof
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

4.  Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease.

Authors:  Leonardo Magro; Mohamad Mohty; Benoit Catteau; Valérie Coiteux; Patrice Chevallier; Louis Terriou; Jean-Pierre Jouet; Ibrahim Yakoub-Agha
Journal:  Blood       Date:  2009-03-16       Impact factor: 22.113

5.  Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD.

Authors:  L Magro; B Catteau; V Coiteux; B Bruno; J-P Jouet; I Yakoub-Agha
Journal:  Bone Marrow Transplant       Date:  2008-09-01       Impact factor: 5.483

6.  Imatinib for refractory chronic graft-versus-host disease with fibrotic features.

Authors:  Attilio Olivieri; Franco Locatelli; Marco Zecca; Adele Sanna; Michele Cimminiello; Roberto Raimondi; Guido Gini; Nicola Mordini; Adriana Balduzzi; Pietro Leoni; Armando Gabrielli; Andrea Bacigalupo
Journal:  Blood       Date:  2009-04-29       Impact factor: 22.113

7.  Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.

Authors:  Andrew E Schade; Gary L Schieven; Robert Townsend; Anna M Jankowska; Vojkan Susulic; Rosemary Zhang; Hadrian Szpurka; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2007-10-25       Impact factor: 22.113

8.  Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis.

Authors:  Catherine Skhirtladze; Oliver Distler; Clara Dees; Alfiya Akhmetshina; Nicole Busch; Paulius Venalis; Jochen Zwerina; Bernd Spriewald; Margarita Pileckyte; Georg Schett; Jörg H W Distler
Journal:  Arthritis Rheum       Date:  2008-05

9.  Dasatinib in chronic myeloid leukemia: a review.

Authors:  Dolly G Aguilera; Apostolia M Tsimberidou
Journal:  Ther Clin Risk Manag       Date:  2009-05-04       Impact factor: 2.423

10.  Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis.

Authors:  Alfiya Akhmetshina; Clara Dees; Margarita Pileckyte; Britta Maurer; Roland Axmann; Astrid Jüngel; Jochen Zwerina; Steffen Gay; Georg Schett; Oliver Distler; Jörg H W Distler
Journal:  FASEB J       Date:  2008-03-07       Impact factor: 5.191
  10 in total
  2 in total

1.  Graft-versus-host disease: part II. Management of cutaneous graft-versus-host disease.

Authors:  Sharon R Hymes; Amin M Alousi; Edward W Cowen
Journal:  J Am Acad Dermatol       Date:  2012-04       Impact factor: 11.527

2.  Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease.

Authors:  Isabel Sánchez-Ortega; Rocío Parody; Octavio Servitje; Cristina Muniesa; Montserrat Arnan; Beatriz Patino; Anna Sureda; Rafael F Duarte
Journal:  Croat Med J       Date:  2016-06-30       Impact factor: 1.351
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.